Navigation Links
Early Detection Push from New Alzheimer's Disease Discussion Group Points to Advances by Startup Companies, Including Louisville-Based Neuronetrix, Inc.
Date:12/28/2007

LOUISVILLE, Ky., Dec. 28 /PRNewswire/ -- Recent discussions about screening for Alzheimer's disease have begun to stimulate interest in advanced diagnostic technologies. A new advisory group, called AD Screening Discussion Group, has recommended screening for Alzheimer's as patients become eligible for Medicare. The COGNISION(TM) System being developed by Neuronetrix, Inc. is a new Alzheimer's screening technology which will be entering clinical trials in Q1 2008. The COGNISION(TM) System uses proprietary pattern recognition algorithms to classify the patient's brainwave responses based on similarities to known neurological disease profiles. The test is non- invasive, inexpensive, and can be performed in a doctor's office.

Neuronetrix, based in Louisville, KY, will revolutionize the treatment of patients with neurologic disorders by providing meaningful screening information to physicians early in the disease process. Its patent-pending COGNISION(TM) System will "for the first time, directly detect the cognitive deficits associated with Alzheimer's disease," according to K.C. Fadem, inventor of the COGNISION(TM) System.

Alzheimer's is a chronic neurodegenerative disease which afflicts roughly 5 million individuals in the United States. Traditionally, a diagnosis is only made once significant symptoms are present, often 2-4 years into the symptomatic phase of the disease.

"Routine screening is not currently a reality, but it is now appropriate to allow for this, based on the burgeoning senior population in our country and the immense cost to society," according to Dr. Paul R. Solomon, Professor, Department of Psychology and Neuroscience, Williams College; and a member of the AD Screening Discussion Group.

Currently Alzheimer's patients incur direct Medicare/Medicaid costs of more than $50 billion per year, according to the Alzheimer's Association. Mike Reid, CEO of Neuronetrix, indicated that a conservative 5% penetration rate for COGNISION(TM) screening would represent almost $7 billion per year in Americans' cost savings for Alzheimer's care. These savings would be realized by delaying the point at which Alzheimer's sufferers would have to be placed in a long-term care facility. This delay will be due to earlier treatment with current Alzheimer's drugs such as Aricept(R) from Pfizer, Inc. and through treatment with potentially more effective drugs on the near term horizon.

The AD Screening Discussion Group is comprised of a multi-disciplinary panel of experts convened by Eisai Inc., and Pfizer, Inc., to debate the value of screening and early detection for Alzheimer's disease.

For more information, go to http://www.neuronetrix.com.


'/>"/>
SOURCE Neuronetrix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Eye-staining technique offers early detection for dry eye syndrome
3. Early Weight Loss in Women Linked to Dementia
4. Isolation of a new gene family essential for early development
5. U of M study: Early treatment can reverse heart damage
6. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Pop stars more than twice as likely to die an early death
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. Research says doctors gender may hinder early diagnosis of heart disease in women
11. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... overview on laser diffraction analysis as a tool to characterize particle size distributions ... potential to obtain improved results and novel scientific findings. It describes methods of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... BC (PRWEB) , ... February 27, 2017 , ... ... drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ ... to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... San Francisco and environs, is proud to announce an upgrade to the company's ... the upgraded Yelp page on topics as diverse as Platelet Rich Plasma (PRP) ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  A ... P. Vallely , MBBS, PhD, FRACS, of  Sydney ... University of Sydney will be published in ... of the American College of Cardiology ... beating heart bypass surgery technique (anOPCABG) reduced ...
(Date:2/27/2017)... Biophysics Corporation, a global medical device manufacturer based in ... growth in 2016 when compared to the previous year based ... fueled by its AffloVest® sales in the United ... global sales of surgical product lines. Said H. ... 25 th year in delivering high-quality, innovative medical devices ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
Breaking Medicine Technology: